Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting this week. The study was conducted using our mouse surrogate molecule in an in-house developed mouse model of NASH with elevated hepatic HSD expression. HSD17B13 is a genetically identified target strongly associated with liver steatosis and fibrosis. However the mode of action still remains unknown and very little preclinical reversibility data has been shown up to now. Ribo’s HSD program is a siRNA molecule based on our proprietary Ribo-GalSTAR delivery system and is about to enter IND-enabling phase.
Ribocure Pharmaceuticals and Ribo Life Science announce appointment of John Taylor to Vice President, Head of Global Business Development
John Taylor has joined Ribocure Pharmaceuticals AB as Vice President